Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Abby Statler , Annie Gupta , Cassann N. Blake , Wei (Auston) Wei , Brian P Hobbs , Zeina A. Nahleh
Background: Determinants of variation in therapy utilization and OS are unclear for patients diagnosed with hormone receptor+, human epidermal growth factor 2 positive (HER2+) MBC. This study aimed to identify if there are disparities in first-line treatment patterns and outcomes for this subpopulation of MBC patients. Methods: We analyzed MBC patients included in the National Cancer Database diagnosed with estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) and HER2+ disease (i.e. triple positive) treated with endocrine therapy or chemotherapy between 2010 and 2015. Analyses describe the distribution of treatments administered in the first-line setting. Kaplan-Meier method was used to estimate distributions of OS, which were compared among patient cohorts using the log-rank test. Results: Of the 6215 patients diagnosed with triple positive MBC, the majority were 50-70 years old (n=3414 [55%]), female (n= 6122 [98%]), and white (n=4478 [72%]). Four distinct treatment patters were identified; hormonal therapy was the most common (n= 2289 [37%]), followed by hormonal therapy + anit-HER2 (n=1471 [24%]), chemotherapy (1280 [20%]), and chemotherapy + anit-HER2 (n=1175 (19%)). Significant differences in demographic, socioeconomic, and disease characteristics were identified across groups. Disparities in OS were also observed; the unadjusted 5-year OS was substantially lower among older patients, African Americans (AA), those with government insurance, and lower income (Table). Conclusions: This is the first study to report disparities in treatment patterns and OS among real-world triple positive MBC patients. Further investigation is required to determine if there are independent causal associations between poor prognosis and the identified demographic and socioeconomic characteristics.
Factor | Level | Median 5 year OS | P-value |
---|---|---|---|
Age | <50 | 0.55 | < 0.0001 |
50-70 | 0.39 | ||
>70 | 0.20 | ||
Sex | Female | 0.40 | 0.02 |
Male | 0.24 | ||
Race | White (Non-Hispanic) | 0.40 | <0.0001 |
AA | 0.31 | ||
Asian | 0.52 | ||
Hispanic/Latinos | 0.53 | ||
Others | 0.68 | ||
Insurance | Government | 0.28 | <0.0001 |
Not Insured | 0.40 | ||
Private | 0.52 | ||
Income | <38K | 0.28 | <0.0001 |
38-68 K | 0.39 | ||
>68 K | 0.48 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kohei Shitara
2020 ASCO Virtual Scientific Program
First Author: Santiago Escrivá
2024 ASCO Genitourinary Cancers Symposium
First Author: Siqi Hu
First Author: Nicholas Patrick McAndrew